Welcome to our dedicated page for Generation Bio Co. news (Ticker: GBIO), a resource for investors and traders seeking the latest updates and insights on Generation Bio Co. stock.
Generation Bio Co. (NASDAQ: GBIO) is a clinical-stage biotechnology company advancing nonviral genetic medicines through its proprietary cell-targeted lipid nanoparticle (ctLNP) and immune-quiet DNA (iqDNA) platforms. This page serves as the definitive source for official company announcements, including clinical trial milestones, strategic partnerships, and scientific advancements.
Key Resources: Access real-time updates on GBIO’s progress in developing re-dosable gene therapies for liver diseases, retinal disorders, and autoimmune conditions. Content categories include regulatory filings, research publications, and executive leadership insights. Investors will find earnings reports and corporate governance announcements alongside updates on manufacturing scalability.
Why Bookmark This Page: Stay informed about innovations in nonviral delivery systems designed to overcome immunogenicity challenges. Our curated news collection ensures you never miss critical developments in GBIO’s pipeline or technology enhancements. Check back regularly for verified updates directly from the company and trusted industry sources.
Generation Bio Co. (Nasdaq: GBIO) reported second quarter 2022 financial results, focusing on advancements in its genetic medicine platform. The company has a cash balance of $312.2 million, projected to fund operations into 2025. Key developments include a new modular manufacturing strategy for its closed-ended DNA (ceDNA) product, enhancing productivity and capital efficiency. The net loss for the quarter increased to $37.9 million, or $0.66 per share, compared to $30.8 million or $0.55 per share in the previous year.
Generation Bio Co. (Nasdaq: GBIO) announced its participation in the virtual 2022 Wedbush PacGrow Healthcare Conference scheduled for August 9th at 9:45 a.m. ET. The event will include a live webcast available on the company’s investor website, with a replay accessible for 30 days post-event. Generation Bio is focused on advancing genetic medicines using its unique non-viral platform, which aims to provide durable, redosable treatments for rare and prevalent diseases, utilizing innovative technologies like closed-ended DNA (ceDNA) and cell-targeted lipid nanoparticles.
Generation Bio (Nasdaq: GBIO) announced the appointment of Dannielle Appelhans to its Board of Directors on July 18, 2022. Appelhans, currently COO of Rubius Therapeutics, brings extensive experience in pharmaceutical strategy and operations, including leadership roles at Novartis. Her expertise is expected to aid Generation Bio as it transitions from research to commercialization. Appelhans expressed enthusiasm about contributing to the company's mission of developing novel genetic medicines for rare diseases.
Generation Bio (Nasdaq: GBIO) is revising its GMP manufacturing strategy to optimize efficiency through enhanced rapid enzymatic synthesis (RES) of closed-ended DNA (ceDNA). The company will sublease its planned GMP facility and adopt a smaller, flexible manufacturing footprint, extending its cash runway into 2025. This shift will not affect production timelines for its ongoing liver, retina, and vaccine programs. The RES process allows for high purity and scalability, enabling the company to produce millions of doses with shorter production cycles.
Generation Bio (Nasdaq: GBIO) will have CEO Geoff McDonough participate in a fireside chat at the 2022 Jefferies Healthcare Conference on June 10th at 11:00 a.m. ET in New York. A live webcast of the event will be accessible on the investor section of the company's website, with a replay available for 30 days afterwards.
The company focuses on innovative genetic medicines for rare and prevalent diseases using a unique DNA construct and delivery system aimed at providing durable treatments.
Generation Bio Co. (Nasdaq: GBIO) reported steady progress in optimizing cell-targeted lipid nanoparticles (ctLNPs) for genetic medicines in liver and retina applications, as well as vaccine development. The company maintains a strong cash position of $337.0 million, projected to fund operations into 2024. In Q1 2022, R&D expenses rose to $25.6 million, while G&A expenses increased to $9.8 million, resulting in a net loss of $35.0 million, or $0.61 per share, compared to a net loss of $25.6 million a year earlier.
Generation Bio Co. (Nasdaq: GBIO) announced that its CEO, Geoff McDonough, will participate in the 21st Annual Needham Virtual Healthcare Conference on April 11th at 11:00 a.m. ET. A live webcast of the event will be available on the company’s investor website, with a replay accessible for 30 days post-event. Generation Bio focuses on developing innovative genetic medicines for rare and prevalent diseases, utilizing its proprietary non-viral genetic medicine platform, which includes unique delivery systems and manufacturing processes aimed at providing durable and scalable treatments.
Generation Bio Co. (Nasdaq: GBIO) announced that its CEO, Geoff McDonough, will participate in the Gene Therapy panel at the 42nd Annual Cowen Health Care Conference on March 9 at 12:50 p.m. ET. A live webcast will be available on the investor section of the company's website, with a replay accessible for 30 days following the event.
The company is focused on innovative genetic medicines aimed at providing durable treatments for rare and prevalent diseases, utilizing its proprietary non-viral genetic medicine platform.
Generation Bio Co (Nasdaq: GBIO) reported a cash position of $375.1 million at the end of 2021, expected to fund operations through 2024. The company is focused on advancing its genetic medicine platform, targeting liver diseases and retinal conditions. In 2021, R&D expenses rose to $85.2 million from $58.5 million in 2020. The net loss for 2021 was $119.2 million, a decrease in loss per share from $2.95 to $2.12. The company aims to optimize its delivery systems for ongoing hemophilia A and Stargardt disease programs.
Generation Bio Co. (Nasdaq: GBIO) announced the promotion of Antoinette Paone to chief operating officer (COO). Having previously served as senior vice president and head of regulatory affairs since 2018, she brings over 20 years of experience in the pharmaceutical and biotech sectors. Paone will oversee the company's good manufacturing practice (GMP) capabilities, vital for developing its unique genetic medicine platform, which includes closed-ended DNA constructs and a lipid nanoparticle delivery system. This strategic move is aimed at enhancing operational efficiency and supporting the company's mission to deliver innovative treatments.
FAQ
What is the current stock price of Generation Bio Co. (GBIO)?
What is the market cap of Generation Bio Co. (GBIO)?
